Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
Matinas BioPharma Holdings (NYSE American: MTNB) has announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective February 5, 2025. D'An brings significant experience as a board director and financial leader, with extensive expertise in corporate governance, financial oversight, and accounting across both public and private companies. She is a former partner at Ernst & Young, where she spent 18 years serving clients in retail, consumer products, and technology sectors. In addition to chairing the Audit Committee, D'An will serve as a member of the Matinas Nominating & Governance Committee.
Matinas BioPharma Holdings (NYSE American: MTNB) ha annunciato la nomina di Evelyn D'An nel suo Consiglio di Amministrazione come direttore indipendente e presidente del Comitato di Controllo, a partire dal 5 febbraio 2025. D'An porta con sé una significativa esperienza come direttore di consiglio e leader finanziario, con ampia expertise nella governance aziendale, nella supervisione finanziaria e nella contabilità in aziende sia pubbliche che private. È stata ex partner presso Ernst & Young, dove ha trascorso 18 anni servendo clienti nei settori del retail, dei prodotti di consumo e della tecnologia. Oltre a presiedere il Comitato di Controllo, D'An sarà membro del Comitato di Nomina e Governance di Matinas.
Matinas BioPharma Holdings (NYSE American: MTNB) ha anunciado la designación de Evelyn D'An a su Junta Directiva como directora independiente y presidenta del Comité de Auditoría, a partir del 5 de febrero de 2025. D'An aporta una experiencia significativa como directora de junta y líder financiera, con amplia experiencia en gobernanza corporativa, supervisión financiera y contabilidad en empresas tanto públicas como privadas. Fue socia de Ernst & Young, donde pasó 18 años atendiendo a clientes en los sectores de venta al por menor, productos de consumo y tecnología. Además de presidir el Comité de Auditoría, D'An también será miembro del Comité de Nominación y Gobernanza de Matinas.
Matinas BioPharma Holdings (NYSE American: MTNB)는 Evelyn D'An을 독립 이사 및 감사 위원회 의장으로 이사회의 일원으로 임명했다고 발표했습니다. 임기는 2025년 2월 5일부터 시작됩니다. D'An은 이사로서 및 재무 리더로서 상당한 경험을 가지고 있으며, 공공 및 민간 기업 모두에서 기업 거버넌스, 재무 감독 및 회계에 대한 광범위한 전문 지식을 보유하고 있습니다. 그녀는 Ernst & Young의 전 파트너로, 18년 동안 소매, 소비재 및 기술 부문 고객을 위해 근무했습니다. 감사 위원회를 주재하는 것 외에도, D'An은 Matinas의 추천 및 거버넌스 위원회의 일원으로 활동할 것입니다.
Matinas BioPharma Holdings (NYSE American: MTNB) a annoncé la nomination de Evelyn D'An au Conseil d'Administration en tant qu'administratrice indépendante et présidente du Comité d'Audit, à compter du 5 février 2025. D'An apporte une expérience significative en tant que membre de conseil et leader financier, avec une vaste expertise en gouvernance d'entreprise, supervision financière et comptabilité au sein d'entreprises publiques et privées. Elle a été ancienne partenaire chez Ernst & Young, où elle a servi des clients dans les secteurs du commerce de détail, des produits de consommation et de la technologie pendant 18 ans. En plus de présider le Comité d'Audit, D'An sera également membre du Comité de Nomination et de Gouvernance de Matinas.
Matinas BioPharma Holdings (NYSE American: MTNB) hat die Ernennung von Evelyn D'An in den Vorstand als unabhängige Direktorin und Vorsitzende des Prüfungsausschusses bekannt gegeben, die am 5. Februar 2025 wirksam wird. D'An bringt umfangreiche Erfahrung als Vorstandsmitglied und Finanzleiterin mit, mit umfassender Expertise in der Unternehmensführung, finanzieller Aufsicht und Buchhaltung sowohl in öffentlichen als auch in privaten Unternehmen. Sie war ehemalige Partnerin bei Ernst & Young, wo sie 18 Jahre lang Klienten aus den Bereichen Einzelhandel, Konsumgüter und Technologie betreute. Neben der Leitung des Prüfungsausschusses wird D'An auch Mitglied des Nominierungs- und Governance-Ausschusses von Matinas sein.
- Appointment of experienced financial leader with extensive corporate governance background
- Addition of former Ernst & Young partner with 18 years of professional service experience
- Strengthening of board expertise in audit and financial oversight
- None.
BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D’An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025.
Ms. D’An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D’An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, technology, and other sectors. She will serve as Chair of the Matinas Audit Committee and will also serve as a member of the Matinas Nominating & Governance Committee.
“We are delighted to welcome Evelyn to the Matinas Board,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. “Evelyn’s background as an experienced Audit Committee chair and business leader fills a need, and her commercial and strategic expertise complements the experience of our other Board members. We are honored that she has chosen to join us at this important time for the Company.”
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
For more information, please visit www.matinasbiopharma.com.
Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the appointment of Ms. D’An, and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the sale of MAT 2203, and the evaluation of other alternatives for the Company, including a winddown or dissolution of the Company; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.
FAQ
When did Evelyn D'An join Matinas BioPharma's (MTNB) Board of Directors?
What positions will Evelyn D'An hold at Matinas BioPharma (MTNB)?
What is Evelyn D'An's professional background before joining MTNB?
How will Evelyn D'An's appointment benefit Matinas BioPharma (MTNB)?
